Hyperphosphatemia and Cardiovascular Disease
Hyperphosphatemia or even serum phosphate levels within the “normal laboratory range” are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate le...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.644363/full |
| _version_ | 1818577214692655104 |
|---|---|
| author | Chao Zhou Zhengyu Shi Nan Ouyang Xiongzhong Ruan Xiongzhong Ruan |
| author_facet | Chao Zhou Zhengyu Shi Nan Ouyang Xiongzhong Ruan Xiongzhong Ruan |
| author_sort | Chao Zhou |
| collection | DOAJ |
| description | Hyperphosphatemia or even serum phosphate levels within the “normal laboratory range” are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients. Large randomized clinical trials with hard endpoints are urgently needed to establish a causal relationship between phosphate excess and cardiovascular disease (CVD) and to determine if lowering serum phosphate constitutes an effective intervention for the prevention and treatment of CVD. |
| first_indexed | 2024-12-16T06:26:22Z |
| format | Article |
| id | doaj.art-b3b04290fe224e3c9c31375e66352ed8 |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-12-16T06:26:22Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-b3b04290fe224e3c9c31375e66352ed82022-12-21T22:40:59ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-03-01910.3389/fcell.2021.644363644363Hyperphosphatemia and Cardiovascular DiseaseChao Zhou0Zhengyu Shi1Nan Ouyang2Xiongzhong Ruan3Xiongzhong Ruan4Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaJohn Moorhead Research Laboratory, Centre for Nephrology, University College London (UCL) Medical School, London, United KingdomCentre for Lipid Research and Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaHyperphosphatemia or even serum phosphate levels within the “normal laboratory range” are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients. Large randomized clinical trials with hard endpoints are urgently needed to establish a causal relationship between phosphate excess and cardiovascular disease (CVD) and to determine if lowering serum phosphate constitutes an effective intervention for the prevention and treatment of CVD.https://www.frontiersin.org/articles/10.3389/fcell.2021.644363/fullphosphatecardiovascular diseasevascular calcificationcardiac valvular calcificationatherosclerosisleft ventricular hypertrophy |
| spellingShingle | Chao Zhou Zhengyu Shi Nan Ouyang Xiongzhong Ruan Xiongzhong Ruan Hyperphosphatemia and Cardiovascular Disease Frontiers in Cell and Developmental Biology phosphate cardiovascular disease vascular calcification cardiac valvular calcification atherosclerosis left ventricular hypertrophy |
| title | Hyperphosphatemia and Cardiovascular Disease |
| title_full | Hyperphosphatemia and Cardiovascular Disease |
| title_fullStr | Hyperphosphatemia and Cardiovascular Disease |
| title_full_unstemmed | Hyperphosphatemia and Cardiovascular Disease |
| title_short | Hyperphosphatemia and Cardiovascular Disease |
| title_sort | hyperphosphatemia and cardiovascular disease |
| topic | phosphate cardiovascular disease vascular calcification cardiac valvular calcification atherosclerosis left ventricular hypertrophy |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2021.644363/full |
| work_keys_str_mv | AT chaozhou hyperphosphatemiaandcardiovasculardisease AT zhengyushi hyperphosphatemiaandcardiovasculardisease AT nanouyang hyperphosphatemiaandcardiovasculardisease AT xiongzhongruan hyperphosphatemiaandcardiovasculardisease AT xiongzhongruan hyperphosphatemiaandcardiovasculardisease |